KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 109 filers reported holding KALA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 3.37 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $458,716 | +247.5% | 12,024 | -98.0% | 0.10% | +219.4% |
| Q3 2022 | $132,000 | -26.7% | 601,162 | 0.0% | 0.03% | -35.4% |
| Q2 2022 | $180,000 | -78.3% | 601,162 | 0.0% | 0.05% | -77.0% |
| Q1 2022 | $830,000 | +14.2% | 601,162 | 0.0% | 0.21% | +48.2% |
| Q4 2021 | $727,000 | -53.8% | 601,162 | 0.0% | 0.14% | -42.9% |
| Q3 2021 | $1,575,000 | -50.6% | 601,162 | 0.0% | 0.25% | -37.2% |
| Q2 2021 | $3,186,000 | -21.4% | 601,162 | 0.0% | 0.39% | -47.4% |
| Q1 2021 | $4,052,000 | -0.6% | 601,162 | 0.0% | 0.75% | +82.2% |
| Q4 2020 | $4,076,000 | +20.4% | 601,162 | +33.2% | 0.41% | -56.6% |
| Q3 2020 | $3,384,000 | -5.1% | 451,162 | +33.0% | 0.94% | -17.7% |
| Q2 2020 | $3,564,000 | +533.0% | 339,102 | +429.0% | 1.15% | +254.0% |
| Q1 2020 | $563,000 | – | 64,102 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |